Navigation Links
Vaccine Study in New England Journal of Medicine Wrong in Concluding Mercury Exposures are Harmless, States SafeMinds
Date:9/26/2007

"Study Findings and Limitations Require Further Investigations," Says

Dissenting Panel Member

ATLANTA, Sept. 26 /PRNewswire/ -- A Centers for Disease Control (CDC) study on the relationship between mercury (thimerosal) in vaccines and children's brain functioning draws a misleading conclusion, says one of the study's external consultants, Sallie Bernard, Executive Director of SafeMinds.

"Early Thimerosal Exposure and Neuropsychological Outcomes at 7 to 10 Years," appearing in the New England Journal of Medicine (NEJM, 9/27/07 issue), concludes that the study "does not support a causal association" between thimerosal and neuropsychological outcomes in children. The conclusion misleads the public, implying without qualification that a relationship has been disproved. In fact, "the study was unable to prove either the presence or absence of a causal relationship," noted Bernard, the panel's only consumer representative.

According to Bernard, unlike gold-standard randomized clinical trials, an observational study such as this cannot address causation. If, however, the findings confirm those of other studies, it can contribute to assessments of causality. This study confirmed associations detected in other studies, such as increased rates of motor and verbal tics and poorer language ability. Replication of previous studies was noted in the text but ignored in the Abstract and Concluding statement, which are the sections routinely read by the wider public.

The study's many limitations preclude sweeping conclusions on thimerosal's effects. The small sample size and few children in the highest and lowest exposure groups reduced the study's precision and ability to establish statistical significance. The study only obtained a 30% participation rate, well below the commonly accepted scientific standard of 70%. Early interventions which may have reduced or eliminated some deficits such as speech delays by age 7 to 10 years were not controlled. An analysis of combined prenatal and postnatal mercury exposures was lacking. Newborns weighing 5 lbs 8 ounces or less (9% of births) were excluded even though these infants may be more vulnerable to mercury's effects.

The conclusions should have referenced these and other limitations, as well as confirming thimerosal-associated impairments found in other studies, and as a result, called for further investigation. "Children in the U.S. and worldwide are still given vaccines containing mercury. Health officials should be erring on the side of caution," said Bernard. The data set will be made available to other researchers by the CDC, and Bernard hopes other scientists will apply alternative methodologies to study this important public health issue. She has asked the NEJM to publish her dissenting comments when the study appears online at http://www.nejm.org.

SafeMinds focuses on the role of mercury in neurodevelopmental disorders, including autism. This study did not address autism. A separate CDC-sponsored study investigating thimerosal and autism is underway.


'/>"/>
SOURCE SafeMinds
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
3. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
4. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
5. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
6. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
7. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
8. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
9. New Flu Vaccine from PepTcell Could Provide Immunity Against All Strains of Influenza Virus
10. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
11. New Flu Vaccine From PepTcell Could Provide Immunity Against All Strains of Influenza Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2017)... division of Diplomat Specialty Infusion Group, is celebrating a decade of empowering ... celebrate its anniversary, ThriveRx recently launched a redesigned website at thriverx.diplomat.is ... to create the best user experience for consumers and health care professionals. ... Diplomat Pharmacy ... "We,ve made several great strides throughout the past 10 years," ...
(Date:7/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ... a clinical-stage pharmaceutical company focused on the development of oral ... from the Israel Securities Authority to dual-list its common stock ... will commence trading on the TASE on July 12, 2017 ... of the Company, it is expected that Oramed will be ...
(Date:7/5/2017)... Wash. , July 5, 2017   BioLife ... leading developer, manufacturer and marketer of proprietary clinical grade ... cryopreservation freeze media ("BioLife"), today announced that it ... its debt holder and largest shareholder, to modify its ... Pursuant to the modification, WAVI agreed to exchange ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... Sharon Kleyne ... signature product of her research center at Bio-Logic Aqua Research® Water Life Science®, ... the greatest number of sufferers of blindness. “We think that Nature’s Tears® EyeMist® ...
(Date:7/21/2017)... TORONTO, ONTARIO, CANADA (PRWEB) , ... July 21, ... ... may give insight into why concussion rates are on the rise, say researchers ... Annual Meeting today in Toronto, Ontario, Canada. , “The combination of evaluating the ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... enterprise-grade IT operations analytics and application performance monitoring (APM) solutions, has expanded ... healthcare services providers. , According to Peter Ohrenberger, sales director at Nastel, ...
(Date:7/20/2017)... ... July 20, 2017 , ... Team Type 1 Foundation, a ... for everyone affected by diabetes, is teaming up with a Microsoft Corp. employee-led hackathon ... off on July 24th. , “Team Type 1’s mission overlaps seamlessly with Microsoft’s ...
(Date:7/20/2017)... ... July 20, 2017 , ... Using CDRH’s Medical Device ... — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/mdqualitydata          , Device makers ... It’s known as the “CY2016 Annual FDA Medical Device Quality System Data” report. ...
Breaking Medicine News(10 mins):